Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Sodium Methanesulfinate (CAS: 20277-69-4) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Sodium Methanesulfinate, Please contact: alvin@ruifuchem.com
| Lapatinib Base |
CAS 231277-92-2 |
| Lapatinib Ditosylate Monohydrate |
CAS 388082-78-8 |
| Sodium Methanesulfinate |
CAS 20277-69-4 |
| 3-Chloro-4-(3-Fluorobenzyloxy)aniline |
CAS 202197-26-0 |
| 2-Aminoethyl Methyl Sulfone Hydrochloride |
CAS 104458-24-4 |
| 4-Chloro-6-Iodoquinazoline |
CAS 98556-31-1 |
| 6-Iodo-4-Hydroxyquinazoline |
CAS 16064-08-7 |
| 5-Formyl-2-Furanboronic Acid |
CAS 27329-70-0 |
| 5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde |
CAS 231278-84-5 |
| Chemical Name |
Sodium Methanesulfinate |
| Synonyms |
Methanesulfinic Acid Sodium Salt |
| CAS Number |
20277-69-4 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
CH5NaO2S |
| Molecular Weight |
104.1 |
| Melting Point |
222.0~226.0℃(dec.) (lit.) |
| Water Solubility |
Soluble in Water |
| Sensitive |
Air Sensitive & Hygroscopic |
| COA & MSDS |
Available |
| Origin |
Shanghai, China |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Off-White Crystal Powder |
| Purity |
>96.0% |
| Loss on drying |
<1.00% |
| Infrared Spectrum |
Conforms to Structure |
| Proton NMR Spectrum |
Conforms to Structure |
| Test Standard |
Enterprise Standard |
| Usage |
Pharmaceutical Intermediates; Organic Synthesis |
| Hazard Symbols |
Xn - Harmful |
| Risk Codes |
R22 - Harmful if swallowed |
| R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
| Safety Description |
S36/37 - Wear suitable protective clothing and gloves. |
| S24/25 - Avoid contact with skin and eyes. |
| UN IDs |
2811 |
| WGK Germany |
3 |
| Packing Group |
III |
Shanghai Ruifu Chemical Co., Ltd. commercial supply Sodium Methanesulfinate (CAS: 20277-69-4). It is an important pharmaceutical intermediate, which can be used in the prodcution of API (CAS 231277-92-2) and (CAS 388082-78-8) API or other intermediates. (CAS 388082-78-8), a new member of the 4-anilinoquinazoline class of RTK inhibitors (RTKIs), was launched as an oral treatment for breast cancer. It has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated in combination with Capecitabine for treating patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.